Eligibility Criteria

Age: From 18 Years To 99 Years

Gender: Both

Inclusion Criteria

• Male or female, at least 18 years of age at time of screening.

• Screening laboratory result indicating HCV GT1 - 6 infection.

• Subject is a recipient of a cadaveric or living donor liver transplant which was a consequence of HCV infection at least 3 months prior to screening Or Subject received a cadaveric or living donor kidney at least 3 months before screening.

• Subjects must be documented as non-cirrhotic.

• Subject is currently taking a stable immunosuppression regimen based on tacrolimus, sirolimus, everolimus, mycophenolate mofetil, azathioprine, and/or cyclosporine.

Exclusion Criteria

• Female subject who is pregnant, breastfeeding or is considering becoming pregnant during the study or for approximately 30 days after the last dose of study drug.

• Clinical history of fibrosing cholestatic hepatitis post-transplant.

• Re-transplantation of the liver or kidney.

• Steroid resistant rejection of the transplanted liver or kidney, or a history of rejection treated with high dose steroid within 3 months of screening.

• History of post-transplant complications related to hepatic or renal vasculature.